Predictors of Unexplained Early Neurological Deterioration After Endovascular Treatment for Acute Ischemic Stroke
BACKGROUND AND PURPOSE:Although the efficacy of endovascular treatment (EVT) in patients with anterior circulation ischemic stroke (AIS) is well documented, early neurological deterioration after EVT remains a serious issue associated with poor outcome. Besides obvious causes, such as lack of reperf...
Gespeichert in:
Veröffentlicht in: | Stroke (1970) 2020-10, Vol.51 (10), p.2943-2950 |
---|---|
Hauptverfasser: | , , , , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 2950 |
---|---|
container_issue | 10 |
container_start_page | 2943 |
container_title | Stroke (1970) |
container_volume | 51 |
creator | Girot, Jean-Baptiste Richard, Sébastien Gariel, Florent Sibon, Igor Labreuche, Julien Kyheng, Maéva Gory, Benjamin Dargazanli, Cyril Maier, Benjamin Consoli, Arturo Daumas-Duport, Benjamin Lapergue, Bertrand Bourcier, Romain |
description | BACKGROUND AND PURPOSE:Although the efficacy of endovascular treatment (EVT) in patients with anterior circulation ischemic stroke (AIS) is well documented, early neurological deterioration after EVT remains a serious issue associated with poor outcome. Besides obvious causes, such as lack of reperfusion, procedural complications, or parenchymal hemorrhage, early neurological deterioration may remain unexplained (UnEND). Our aim was to investigate predictors of UnEND after EVT in patients with AIS.
METHODS:Patients who underwent EVT for AIS, with an initial National Institutes of Health Stroke Scale score >5, Alberta Stroke Program Early CT Score ≥6, and included in a multicenter prospective observational registry were analyzed. Predictors of UnEND, defined as ≥4-point increase in the National Institutes of Health Stroke Scale score between baseline and day 1 after EVT, were determined via center-adjusted analyses.
RESULTS:Among the 1925 included in the analysis, 128 UnEND (6.6%) were recorded. In multivariate analysis, predictors of UnEND were diabetes mellitus (odds ratio [OR], 2.17 [95% CI, 1.32–3.56]), prestroke modified Rankin Scale score ≥2 (OR, 2.22 [95% CI, 1.09–4.55]), general anesthesia (OR, 2.55 [95% CI, 1.51–4.30]), admission systolic blood pressure (OR, 1.10 [95% CI, 1.01–1.20]), age (OR, 1.38 [95% CI, 1.14–1.67]), number of passes (OR, 1.16 [95% CI, 1.04–1.28]), direct admission or not to a comprehensive stroke center (OR, 0.49 [95% CI, 0.30–0.81]), and initial National Institutes of Health Stroke Scale score (OR, 0.65 [95% CI, 0.52–0.81]).
CONCLUSIONS:Severely impaired AIS patients with nonmodifiable factors are more likely to develop UnEND. Some modifiable predictors of UnEND such as the number of EVT passes could be the object of improvement in AIS management. |
doi_str_mv | 10.1161/STROKEAHA.120.029494 |
format | Article |
fullrecord | <record><control><sourceid>pubmed_hal_p</sourceid><recordid>TN_cdi_hal_primary_oai_HAL_hal_03280043v1</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>32921260</sourcerecordid><originalsourceid>FETCH-LOGICAL-c5324-e94b495360fed801586e1b96737084cfee834000d43193d2cabe5ab97bb082bd3</originalsourceid><addsrcrecordid>eNqFkE1v1DAQhi0EokvhHyDkK4dsxx_58DEqW7bqiiK6PVuOM2FDvfFiJy3993gV2CMcLGtG7zPS-xDynsGSsYJd3G2_3d6s6nW9ZByWwJVU8gVZsJzLTBa8ekkWAEJlXCp1Rt7E-AMAuKjy1-RMcMUZL2BBfn4N2PZ29CFS39H7AX8dnOkHbOnKBPdMv-AUvPPfe2sc_YQjht4HM_Z-oHWXJroaWv9oop2cCXQb0Ix7HEba-UBrO41Ir6Pd4b639G4M_gHfkledcRHf_fnPyf3Vanu5zja3n68v601mc5EqoJKNVLkooMO2ApZXBbJGFaUooZK2Q6yETI1aKZgSLbemwdw0qmwaqHjTinPycb67M04fQr834Vl70-t1vdHHHQheAUjxyFJWzlkbfIwBuxPAQB9t65NtnWzr2XbCPszYYWr22J6gv3pToJoDT94lV_HBTU8Y9A6NG3f_uy3_gabiUBYlZBw4sOOUpce4-A0ZPZ38</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Predictors of Unexplained Early Neurological Deterioration After Endovascular Treatment for Acute Ischemic Stroke</title><source>MEDLINE</source><source>American Heart Association Journals</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Alma/SFX Local Collection</source><source>Journals@Ovid Complete</source><creator>Girot, Jean-Baptiste ; Richard, Sébastien ; Gariel, Florent ; Sibon, Igor ; Labreuche, Julien ; Kyheng, Maéva ; Gory, Benjamin ; Dargazanli, Cyril ; Maier, Benjamin ; Consoli, Arturo ; Daumas-Duport, Benjamin ; Lapergue, Bertrand ; Bourcier, Romain</creator><creatorcontrib>Girot, Jean-Baptiste ; Richard, Sébastien ; Gariel, Florent ; Sibon, Igor ; Labreuche, Julien ; Kyheng, Maéva ; Gory, Benjamin ; Dargazanli, Cyril ; Maier, Benjamin ; Consoli, Arturo ; Daumas-Duport, Benjamin ; Lapergue, Bertrand ; Bourcier, Romain ; ETIS Investigators</creatorcontrib><description>BACKGROUND AND PURPOSE:Although the efficacy of endovascular treatment (EVT) in patients with anterior circulation ischemic stroke (AIS) is well documented, early neurological deterioration after EVT remains a serious issue associated with poor outcome. Besides obvious causes, such as lack of reperfusion, procedural complications, or parenchymal hemorrhage, early neurological deterioration may remain unexplained (UnEND). Our aim was to investigate predictors of UnEND after EVT in patients with AIS.
METHODS:Patients who underwent EVT for AIS, with an initial National Institutes of Health Stroke Scale score >5, Alberta Stroke Program Early CT Score ≥6, and included in a multicenter prospective observational registry were analyzed. Predictors of UnEND, defined as ≥4-point increase in the National Institutes of Health Stroke Scale score between baseline and day 1 after EVT, were determined via center-adjusted analyses.
RESULTS:Among the 1925 included in the analysis, 128 UnEND (6.6%) were recorded. In multivariate analysis, predictors of UnEND were diabetes mellitus (odds ratio [OR], 2.17 [95% CI, 1.32–3.56]), prestroke modified Rankin Scale score ≥2 (OR, 2.22 [95% CI, 1.09–4.55]), general anesthesia (OR, 2.55 [95% CI, 1.51–4.30]), admission systolic blood pressure (OR, 1.10 [95% CI, 1.01–1.20]), age (OR, 1.38 [95% CI, 1.14–1.67]), number of passes (OR, 1.16 [95% CI, 1.04–1.28]), direct admission or not to a comprehensive stroke center (OR, 0.49 [95% CI, 0.30–0.81]), and initial National Institutes of Health Stroke Scale score (OR, 0.65 [95% CI, 0.52–0.81]).
CONCLUSIONS:Severely impaired AIS patients with nonmodifiable factors are more likely to develop UnEND. Some modifiable predictors of UnEND such as the number of EVT passes could be the object of improvement in AIS management.</description><identifier>ISSN: 0039-2499</identifier><identifier>EISSN: 1524-4628</identifier><identifier>DOI: 10.1161/STROKEAHA.120.029494</identifier><identifier>PMID: 32921260</identifier><language>eng</language><publisher>United States: American Heart Association, Inc</publisher><subject>Aged ; Aged, 80 and over ; Bioengineering ; Brain Ischemia - drug therapy ; Brain Ischemia - therapy ; Combined Modality Therapy ; Computer Science ; Endovascular Procedures - adverse effects ; Female ; Fibrinolytic Agents - adverse effects ; Fibrinolytic Agents - therapeutic use ; Human health and pathology ; Humans ; Life Sciences ; Male ; Medical Imaging ; Middle Aged ; Nuclear medicine ; Prospective Studies ; Registries ; Risk Factors ; Stroke - drug therapy ; Stroke - therapy ; Thrombectomy - adverse effects ; Treatment Outcome</subject><ispartof>Stroke (1970), 2020-10, Vol.51 (10), p.2943-2950</ispartof><rights>American Heart Association, Inc.</rights><rights>2020 American Heart Association, Inc.</rights><rights>Distributed under a Creative Commons Attribution 4.0 International License</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c5324-e94b495360fed801586e1b96737084cfee834000d43193d2cabe5ab97bb082bd3</citedby><cites>FETCH-LOGICAL-c5324-e94b495360fed801586e1b96737084cfee834000d43193d2cabe5ab97bb082bd3</cites><orcidid>0000-0003-4636-2034 ; 0000-0001-8424-4464 ; 0000-0002-6506-4019 ; 0000-0002-5650-828X ; 0000-0002-1171-4215 ; 0000-0002-0029-1835 ; 0000-0001-9788-4516 ; 0000-0001-6112-0661 ; 0000-0002-2780-6907 ; 0000-0001-9479-3598 ; 0000-0002-6704-3158 ; 0000-0003-0911-8999 ; 0000-0002-1977-5987 ; 0000-0001-9165-5763 ; 0000-0003-1306-1008 ; 0000-0002-4665-1461 ; 0000-0002-0945-5656 ; 0000-0001-5059-4095 ; 0000-0003-0632-3399 ; 0000-0002-6943-9922 ; 0000-0001-8428-9101 ; 0000-0001-8677-2447 ; 0000-0001-6352-7713 ; 0000-0002-8712-8431 ; 0000-0002-0909-8900 ; 0000-0001-6640-8541 ; 0000-0001-5801-0816 ; 0000-0002-5696-5368 ; 0000-0002-2134-0691 ; 0000-0002-2087-5563 ; 0000-0003-3911-1800 ; 0000-0002-3975-3865 ; 0000-0003-2027-2276 ; 0000-0003-2950-8759 ; 0000-0002-1354-4328 ; 0000-0001-8422-9205 ; 0000-0003-1891-9157 ; 0000-0003-0594-4409 ; 0000-0002-8915-0915 ; 0000-0002-6748-8528 ; 0000-0002-7611-7753</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,776,780,881,3674,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32921260$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttps://hal.univ-lorraine.fr/hal-03280043$$DView record in HAL$$Hfree_for_read</backlink></links><search><creatorcontrib>Girot, Jean-Baptiste</creatorcontrib><creatorcontrib>Richard, Sébastien</creatorcontrib><creatorcontrib>Gariel, Florent</creatorcontrib><creatorcontrib>Sibon, Igor</creatorcontrib><creatorcontrib>Labreuche, Julien</creatorcontrib><creatorcontrib>Kyheng, Maéva</creatorcontrib><creatorcontrib>Gory, Benjamin</creatorcontrib><creatorcontrib>Dargazanli, Cyril</creatorcontrib><creatorcontrib>Maier, Benjamin</creatorcontrib><creatorcontrib>Consoli, Arturo</creatorcontrib><creatorcontrib>Daumas-Duport, Benjamin</creatorcontrib><creatorcontrib>Lapergue, Bertrand</creatorcontrib><creatorcontrib>Bourcier, Romain</creatorcontrib><creatorcontrib>ETIS Investigators</creatorcontrib><title>Predictors of Unexplained Early Neurological Deterioration After Endovascular Treatment for Acute Ischemic Stroke</title><title>Stroke (1970)</title><addtitle>Stroke</addtitle><description>BACKGROUND AND PURPOSE:Although the efficacy of endovascular treatment (EVT) in patients with anterior circulation ischemic stroke (AIS) is well documented, early neurological deterioration after EVT remains a serious issue associated with poor outcome. Besides obvious causes, such as lack of reperfusion, procedural complications, or parenchymal hemorrhage, early neurological deterioration may remain unexplained (UnEND). Our aim was to investigate predictors of UnEND after EVT in patients with AIS.
METHODS:Patients who underwent EVT for AIS, with an initial National Institutes of Health Stroke Scale score >5, Alberta Stroke Program Early CT Score ≥6, and included in a multicenter prospective observational registry were analyzed. Predictors of UnEND, defined as ≥4-point increase in the National Institutes of Health Stroke Scale score between baseline and day 1 after EVT, were determined via center-adjusted analyses.
RESULTS:Among the 1925 included in the analysis, 128 UnEND (6.6%) were recorded. In multivariate analysis, predictors of UnEND were diabetes mellitus (odds ratio [OR], 2.17 [95% CI, 1.32–3.56]), prestroke modified Rankin Scale score ≥2 (OR, 2.22 [95% CI, 1.09–4.55]), general anesthesia (OR, 2.55 [95% CI, 1.51–4.30]), admission systolic blood pressure (OR, 1.10 [95% CI, 1.01–1.20]), age (OR, 1.38 [95% CI, 1.14–1.67]), number of passes (OR, 1.16 [95% CI, 1.04–1.28]), direct admission or not to a comprehensive stroke center (OR, 0.49 [95% CI, 0.30–0.81]), and initial National Institutes of Health Stroke Scale score (OR, 0.65 [95% CI, 0.52–0.81]).
CONCLUSIONS:Severely impaired AIS patients with nonmodifiable factors are more likely to develop UnEND. Some modifiable predictors of UnEND such as the number of EVT passes could be the object of improvement in AIS management.</description><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Bioengineering</subject><subject>Brain Ischemia - drug therapy</subject><subject>Brain Ischemia - therapy</subject><subject>Combined Modality Therapy</subject><subject>Computer Science</subject><subject>Endovascular Procedures - adverse effects</subject><subject>Female</subject><subject>Fibrinolytic Agents - adverse effects</subject><subject>Fibrinolytic Agents - therapeutic use</subject><subject>Human health and pathology</subject><subject>Humans</subject><subject>Life Sciences</subject><subject>Male</subject><subject>Medical Imaging</subject><subject>Middle Aged</subject><subject>Nuclear medicine</subject><subject>Prospective Studies</subject><subject>Registries</subject><subject>Risk Factors</subject><subject>Stroke - drug therapy</subject><subject>Stroke - therapy</subject><subject>Thrombectomy - adverse effects</subject><subject>Treatment Outcome</subject><issn>0039-2499</issn><issn>1524-4628</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkE1v1DAQhi0EokvhHyDkK4dsxx_58DEqW7bqiiK6PVuOM2FDvfFiJy3993gV2CMcLGtG7zPS-xDynsGSsYJd3G2_3d6s6nW9ZByWwJVU8gVZsJzLTBa8ekkWAEJlXCp1Rt7E-AMAuKjy1-RMcMUZL2BBfn4N2PZ29CFS39H7AX8dnOkHbOnKBPdMv-AUvPPfe2sc_YQjht4HM_Z-oHWXJroaWv9oop2cCXQb0Ix7HEba-UBrO41Ir6Pd4b639G4M_gHfkledcRHf_fnPyf3Vanu5zja3n68v601mc5EqoJKNVLkooMO2ApZXBbJGFaUooZK2Q6yETI1aKZgSLbemwdw0qmwaqHjTinPycb67M04fQr834Vl70-t1vdHHHQheAUjxyFJWzlkbfIwBuxPAQB9t65NtnWzr2XbCPszYYWr22J6gv3pToJoDT94lV_HBTU8Y9A6NG3f_uy3_gabiUBYlZBw4sOOUpce4-A0ZPZ38</recordid><startdate>20201001</startdate><enddate>20201001</enddate><creator>Girot, Jean-Baptiste</creator><creator>Richard, Sébastien</creator><creator>Gariel, Florent</creator><creator>Sibon, Igor</creator><creator>Labreuche, Julien</creator><creator>Kyheng, Maéva</creator><creator>Gory, Benjamin</creator><creator>Dargazanli, Cyril</creator><creator>Maier, Benjamin</creator><creator>Consoli, Arturo</creator><creator>Daumas-Duport, Benjamin</creator><creator>Lapergue, Bertrand</creator><creator>Bourcier, Romain</creator><general>American Heart Association, Inc</general><general>American Heart Association</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>1XC</scope><orcidid>https://orcid.org/0000-0003-4636-2034</orcidid><orcidid>https://orcid.org/0000-0001-8424-4464</orcidid><orcidid>https://orcid.org/0000-0002-6506-4019</orcidid><orcidid>https://orcid.org/0000-0002-5650-828X</orcidid><orcidid>https://orcid.org/0000-0002-1171-4215</orcidid><orcidid>https://orcid.org/0000-0002-0029-1835</orcidid><orcidid>https://orcid.org/0000-0001-9788-4516</orcidid><orcidid>https://orcid.org/0000-0001-6112-0661</orcidid><orcidid>https://orcid.org/0000-0002-2780-6907</orcidid><orcidid>https://orcid.org/0000-0001-9479-3598</orcidid><orcidid>https://orcid.org/0000-0002-6704-3158</orcidid><orcidid>https://orcid.org/0000-0003-0911-8999</orcidid><orcidid>https://orcid.org/0000-0002-1977-5987</orcidid><orcidid>https://orcid.org/0000-0001-9165-5763</orcidid><orcidid>https://orcid.org/0000-0003-1306-1008</orcidid><orcidid>https://orcid.org/0000-0002-4665-1461</orcidid><orcidid>https://orcid.org/0000-0002-0945-5656</orcidid><orcidid>https://orcid.org/0000-0001-5059-4095</orcidid><orcidid>https://orcid.org/0000-0003-0632-3399</orcidid><orcidid>https://orcid.org/0000-0002-6943-9922</orcidid><orcidid>https://orcid.org/0000-0001-8428-9101</orcidid><orcidid>https://orcid.org/0000-0001-8677-2447</orcidid><orcidid>https://orcid.org/0000-0001-6352-7713</orcidid><orcidid>https://orcid.org/0000-0002-8712-8431</orcidid><orcidid>https://orcid.org/0000-0002-0909-8900</orcidid><orcidid>https://orcid.org/0000-0001-6640-8541</orcidid><orcidid>https://orcid.org/0000-0001-5801-0816</orcidid><orcidid>https://orcid.org/0000-0002-5696-5368</orcidid><orcidid>https://orcid.org/0000-0002-2134-0691</orcidid><orcidid>https://orcid.org/0000-0002-2087-5563</orcidid><orcidid>https://orcid.org/0000-0003-3911-1800</orcidid><orcidid>https://orcid.org/0000-0002-3975-3865</orcidid><orcidid>https://orcid.org/0000-0003-2027-2276</orcidid><orcidid>https://orcid.org/0000-0003-2950-8759</orcidid><orcidid>https://orcid.org/0000-0002-1354-4328</orcidid><orcidid>https://orcid.org/0000-0001-8422-9205</orcidid><orcidid>https://orcid.org/0000-0003-1891-9157</orcidid><orcidid>https://orcid.org/0000-0003-0594-4409</orcidid><orcidid>https://orcid.org/0000-0002-8915-0915</orcidid><orcidid>https://orcid.org/0000-0002-6748-8528</orcidid><orcidid>https://orcid.org/0000-0002-7611-7753</orcidid></search><sort><creationdate>20201001</creationdate><title>Predictors of Unexplained Early Neurological Deterioration After Endovascular Treatment for Acute Ischemic Stroke</title><author>Girot, Jean-Baptiste ; Richard, Sébastien ; Gariel, Florent ; Sibon, Igor ; Labreuche, Julien ; Kyheng, Maéva ; Gory, Benjamin ; Dargazanli, Cyril ; Maier, Benjamin ; Consoli, Arturo ; Daumas-Duport, Benjamin ; Lapergue, Bertrand ; Bourcier, Romain</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c5324-e94b495360fed801586e1b96737084cfee834000d43193d2cabe5ab97bb082bd3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Bioengineering</topic><topic>Brain Ischemia - drug therapy</topic><topic>Brain Ischemia - therapy</topic><topic>Combined Modality Therapy</topic><topic>Computer Science</topic><topic>Endovascular Procedures - adverse effects</topic><topic>Female</topic><topic>Fibrinolytic Agents - adverse effects</topic><topic>Fibrinolytic Agents - therapeutic use</topic><topic>Human health and pathology</topic><topic>Humans</topic><topic>Life Sciences</topic><topic>Male</topic><topic>Medical Imaging</topic><topic>Middle Aged</topic><topic>Nuclear medicine</topic><topic>Prospective Studies</topic><topic>Registries</topic><topic>Risk Factors</topic><topic>Stroke - drug therapy</topic><topic>Stroke - therapy</topic><topic>Thrombectomy - adverse effects</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Girot, Jean-Baptiste</creatorcontrib><creatorcontrib>Richard, Sébastien</creatorcontrib><creatorcontrib>Gariel, Florent</creatorcontrib><creatorcontrib>Sibon, Igor</creatorcontrib><creatorcontrib>Labreuche, Julien</creatorcontrib><creatorcontrib>Kyheng, Maéva</creatorcontrib><creatorcontrib>Gory, Benjamin</creatorcontrib><creatorcontrib>Dargazanli, Cyril</creatorcontrib><creatorcontrib>Maier, Benjamin</creatorcontrib><creatorcontrib>Consoli, Arturo</creatorcontrib><creatorcontrib>Daumas-Duport, Benjamin</creatorcontrib><creatorcontrib>Lapergue, Bertrand</creatorcontrib><creatorcontrib>Bourcier, Romain</creatorcontrib><creatorcontrib>ETIS Investigators</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Hyper Article en Ligne (HAL)</collection><jtitle>Stroke (1970)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Girot, Jean-Baptiste</au><au>Richard, Sébastien</au><au>Gariel, Florent</au><au>Sibon, Igor</au><au>Labreuche, Julien</au><au>Kyheng, Maéva</au><au>Gory, Benjamin</au><au>Dargazanli, Cyril</au><au>Maier, Benjamin</au><au>Consoli, Arturo</au><au>Daumas-Duport, Benjamin</au><au>Lapergue, Bertrand</au><au>Bourcier, Romain</au><aucorp>ETIS Investigators</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Predictors of Unexplained Early Neurological Deterioration After Endovascular Treatment for Acute Ischemic Stroke</atitle><jtitle>Stroke (1970)</jtitle><addtitle>Stroke</addtitle><date>2020-10-01</date><risdate>2020</risdate><volume>51</volume><issue>10</issue><spage>2943</spage><epage>2950</epage><pages>2943-2950</pages><issn>0039-2499</issn><eissn>1524-4628</eissn><abstract>BACKGROUND AND PURPOSE:Although the efficacy of endovascular treatment (EVT) in patients with anterior circulation ischemic stroke (AIS) is well documented, early neurological deterioration after EVT remains a serious issue associated with poor outcome. Besides obvious causes, such as lack of reperfusion, procedural complications, or parenchymal hemorrhage, early neurological deterioration may remain unexplained (UnEND). Our aim was to investigate predictors of UnEND after EVT in patients with AIS.
METHODS:Patients who underwent EVT for AIS, with an initial National Institutes of Health Stroke Scale score >5, Alberta Stroke Program Early CT Score ≥6, and included in a multicenter prospective observational registry were analyzed. Predictors of UnEND, defined as ≥4-point increase in the National Institutes of Health Stroke Scale score between baseline and day 1 after EVT, were determined via center-adjusted analyses.
RESULTS:Among the 1925 included in the analysis, 128 UnEND (6.6%) were recorded. In multivariate analysis, predictors of UnEND were diabetes mellitus (odds ratio [OR], 2.17 [95% CI, 1.32–3.56]), prestroke modified Rankin Scale score ≥2 (OR, 2.22 [95% CI, 1.09–4.55]), general anesthesia (OR, 2.55 [95% CI, 1.51–4.30]), admission systolic blood pressure (OR, 1.10 [95% CI, 1.01–1.20]), age (OR, 1.38 [95% CI, 1.14–1.67]), number of passes (OR, 1.16 [95% CI, 1.04–1.28]), direct admission or not to a comprehensive stroke center (OR, 0.49 [95% CI, 0.30–0.81]), and initial National Institutes of Health Stroke Scale score (OR, 0.65 [95% CI, 0.52–0.81]).
CONCLUSIONS:Severely impaired AIS patients with nonmodifiable factors are more likely to develop UnEND. Some modifiable predictors of UnEND such as the number of EVT passes could be the object of improvement in AIS management.</abstract><cop>United States</cop><pub>American Heart Association, Inc</pub><pmid>32921260</pmid><doi>10.1161/STROKEAHA.120.029494</doi><tpages>8</tpages><orcidid>https://orcid.org/0000-0003-4636-2034</orcidid><orcidid>https://orcid.org/0000-0001-8424-4464</orcidid><orcidid>https://orcid.org/0000-0002-6506-4019</orcidid><orcidid>https://orcid.org/0000-0002-5650-828X</orcidid><orcidid>https://orcid.org/0000-0002-1171-4215</orcidid><orcidid>https://orcid.org/0000-0002-0029-1835</orcidid><orcidid>https://orcid.org/0000-0001-9788-4516</orcidid><orcidid>https://orcid.org/0000-0001-6112-0661</orcidid><orcidid>https://orcid.org/0000-0002-2780-6907</orcidid><orcidid>https://orcid.org/0000-0001-9479-3598</orcidid><orcidid>https://orcid.org/0000-0002-6704-3158</orcidid><orcidid>https://orcid.org/0000-0003-0911-8999</orcidid><orcidid>https://orcid.org/0000-0002-1977-5987</orcidid><orcidid>https://orcid.org/0000-0001-9165-5763</orcidid><orcidid>https://orcid.org/0000-0003-1306-1008</orcidid><orcidid>https://orcid.org/0000-0002-4665-1461</orcidid><orcidid>https://orcid.org/0000-0002-0945-5656</orcidid><orcidid>https://orcid.org/0000-0001-5059-4095</orcidid><orcidid>https://orcid.org/0000-0003-0632-3399</orcidid><orcidid>https://orcid.org/0000-0002-6943-9922</orcidid><orcidid>https://orcid.org/0000-0001-8428-9101</orcidid><orcidid>https://orcid.org/0000-0001-8677-2447</orcidid><orcidid>https://orcid.org/0000-0001-6352-7713</orcidid><orcidid>https://orcid.org/0000-0002-8712-8431</orcidid><orcidid>https://orcid.org/0000-0002-0909-8900</orcidid><orcidid>https://orcid.org/0000-0001-6640-8541</orcidid><orcidid>https://orcid.org/0000-0001-5801-0816</orcidid><orcidid>https://orcid.org/0000-0002-5696-5368</orcidid><orcidid>https://orcid.org/0000-0002-2134-0691</orcidid><orcidid>https://orcid.org/0000-0002-2087-5563</orcidid><orcidid>https://orcid.org/0000-0003-3911-1800</orcidid><orcidid>https://orcid.org/0000-0002-3975-3865</orcidid><orcidid>https://orcid.org/0000-0003-2027-2276</orcidid><orcidid>https://orcid.org/0000-0003-2950-8759</orcidid><orcidid>https://orcid.org/0000-0002-1354-4328</orcidid><orcidid>https://orcid.org/0000-0001-8422-9205</orcidid><orcidid>https://orcid.org/0000-0003-1891-9157</orcidid><orcidid>https://orcid.org/0000-0003-0594-4409</orcidid><orcidid>https://orcid.org/0000-0002-8915-0915</orcidid><orcidid>https://orcid.org/0000-0002-6748-8528</orcidid><orcidid>https://orcid.org/0000-0002-7611-7753</orcidid><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0039-2499 |
ispartof | Stroke (1970), 2020-10, Vol.51 (10), p.2943-2950 |
issn | 0039-2499 1524-4628 |
language | eng |
recordid | cdi_hal_primary_oai_HAL_hal_03280043v1 |
source | MEDLINE; American Heart Association Journals; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Alma/SFX Local Collection; Journals@Ovid Complete |
subjects | Aged Aged, 80 and over Bioengineering Brain Ischemia - drug therapy Brain Ischemia - therapy Combined Modality Therapy Computer Science Endovascular Procedures - adverse effects Female Fibrinolytic Agents - adverse effects Fibrinolytic Agents - therapeutic use Human health and pathology Humans Life Sciences Male Medical Imaging Middle Aged Nuclear medicine Prospective Studies Registries Risk Factors Stroke - drug therapy Stroke - therapy Thrombectomy - adverse effects Treatment Outcome |
title | Predictors of Unexplained Early Neurological Deterioration After Endovascular Treatment for Acute Ischemic Stroke |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-03T08%3A57%3A46IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_hal_p&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Predictors%20of%20Unexplained%20Early%20Neurological%20Deterioration%20After%20Endovascular%20Treatment%20for%20Acute%20Ischemic%20Stroke&rft.jtitle=Stroke%20(1970)&rft.au=Girot,%20Jean-Baptiste&rft.aucorp=ETIS%20Investigators&rft.date=2020-10-01&rft.volume=51&rft.issue=10&rft.spage=2943&rft.epage=2950&rft.pages=2943-2950&rft.issn=0039-2499&rft.eissn=1524-4628&rft_id=info:doi/10.1161/STROKEAHA.120.029494&rft_dat=%3Cpubmed_hal_p%3E32921260%3C/pubmed_hal_p%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/32921260&rfr_iscdi=true |